FDA Oncology Announcements

Anti-CD30 ADC × Lymphoid × Clear all

5 Announcements

FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma

Trial: ECHELON-3
Drugs: Adcetris (brentuximab vedotin) · Anti-CD30 antibody-drug conjugate, lenalidomide · Immunomodulatory drugs (IMiDs), rituximab · Anti-CD20 antibody
Condition: Lymphoid

FDA approves brentuximab vedotin in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma

Drugs: Adcetris (brentuximab vedotin) · Anti-CD30 antibody-drug conjugate, doxorubicin · Anthracycline
Condition: Lymphoid

FDA approves brentuximab vedotin for previously untreated sALCL and CD30-expressing PTCL

Trial: ECHELON-2
Drug: ADCETRIS (brentuximab vedotin) · Anti-CD30 antibody-drug conjugate
Condition: Lymphoid

FDA approves Brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma

Drug: ADCETRIS (brentuximab vedotin) · Anti-CD30 antibody-drug conjugate
Condition: Lymphoid

Brentuximab Vedotin Approved for the post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation treatment of patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression

Drug: ADCETRIS (brentuximab vedotin) · Anti-CD30 antibody-drug conjugate
Condition: Lymphoid